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Abstract
Aims/hypothesis—Fenofibrate has been noted to cause an elevation in serum creatinine in
some individuals. Participants in the Action to Control Cardiovascular Risk in Diabetes Lipid
Study were studied to better characterise who is at risk of an increase in creatinine level and to
determine whether those with creatinine elevation have a differential risk of adverse renal or
cardiovascular outcomes.
Methods—A fenofibrate-associated creatinine increase (FACI) was defined as an increase in
serum creatinine of at least 20% from baseline to month 4 in participants assigned to fenofibrate.
Baseline patient characteristics, and baseline and 4-month drug, clinical, laboratory characteristics
and study outcomes were examined by FACI status.
Results—Of the sample, 48% of those randomised to receive fenofibrate had at least a 20%
increase in serum creatinine within 4 months. In multivariable analysis, participants who were
older, male, used an ACE inhibitor at baseline, used a thiazolidinedione (TZD) at 4 months post-
randomisation, had baseline CVD, and had lower baseline serum creatinine and LDL-cholesterol
levels were all more likely to meet the criteria for FACI. Participants in the FACI group were also
more likely to have a decrease in their serum triacylglycerol level from baseline to 4 months. No
differences in study outcomes were seen by FACI criteria.
Conclusions/interpretation—Several characteristics predict a rapid rise in serum creatinine
upon starting fenofibrate. Participants who met the criteria for FACI also had a greater change in
triacylglycerol levels. In the setting of careful renal function surveillance and reduction of
fenofibrate dose as indicated, no increase in renal disease or cardiovascular outcome was seen in
those individuals demonstrating FACI.
Keywords
Cardiovascular; Creatinine; Fenofibrate; Outcomes; Renal
Introduction
Fibrates, including fenofibrate, have been used as lipid-altering medications for more than
four decades. Although the US Food and Drug Administration has recently issued a
communication regarding the lack of incremental benefit of fenofibrate over statin
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monotherapy with regard to the prevention of CVD [1], it remains an important drug for use
in reducing triacylglycerol levels and is the most commonly prescribed fibrate in both the
USA and Canada [2].
As early as 1999, fenofibrate was noted to cause an elevation in serum creatinine in some
individuals shortly after starting the drug [3]. Broeders et al [4] reviewed the data from
seven smaller studies on fenofibrate (144 patients, 200 mg daily dose) and found that serum
creatinine increased from 8 to 18%from baseline upon starting fenofibrate. The Diabetes
Atherosclerosis Intervention Study (DAIS), a clinical trial of the effect of fenofibrate on
heart disease in patients with diabetes, reported similar findings [5]. In 2005, the Fenofibrate
Intervention and Event Lowering in Diabetes (FIELD) study noted an increase in plasma
creatinine of 10–12 µmol/l in the fenofibrate group compared with participants randomised
to placebo [6]. Similar results have been found with other drugs in this class, with the
possible exception of gemfibrozil [7, 8].
Although the increase in serum creatinine level is well-documented, patient characteristics
and possible drug interactions that may precipitate the increase have not been well
characterised. Although initial case reports of increased creatinine with fenofibrate treatment
included patients with impaired renal function, renal transplant and proteinuria, previous
studies have not determined whether impaired renal function is a predictor of creatinine
elevation following fenofibrate therapy [4, 9, 10]. Increased creatinine level has also been
observed in those with normal renal function [11]. Ellen et al examined the co-
administration of simvastatin and fenofibrate as a predictor of the increase in creatinine and
found no additive effect of the two medications [12]. No large study has systematically
examined the predictors of the creatinine increase. Whereas the DAIS and FIELD studies
did report fewer participants in the fenofibrate arm progressing to micro-albuminuria, this
finding has not been examined in other clinical trials [5, 6]. The Action to Control
Cardiovascular Risk in Diabetes (ACCORD) Lipid Trial offers an opportunity to better
understand the aetiology and consequences of the creatinine increase observed in some
patients receiving fenofibrate.
This paper has three aims: first, to determine the characteristics of patients experiencing a
rise in creatinine shortly after starting fenofibrate; second, to determine the longitudinal
pattern of creatinine elevation in these participants; and third, to determine whether the
creatinine elevation predicts a change in renal function, as measured by the albumin/
creatinine ratio, or an increased risk of a cardiovascular outcome.
Methods
Study design
The ACCORD Lipid Study was a 2×2 factorial design trial conducted with patients with
type 2 diabetes. The objective was to determine whether a treatment strategy designed to
raise HDL-cholesterol levels and lower triacylglycerol by the addition of fenofibrate to
statin therapy would have cardiovascular benefits over a strategy targeting primarily LDL-
cholesterol reduction with statin therapy alone. The full details of the study design have been
published elsewhere [13].
ACCORD enrolment began January 2001 and was completed in October 2005. The study
was sponsored by the National Heart Lung and Blood Institute, with 77 clinical sites in the
USA and Canada participating. The protocol was reviewed and approved by the institutional
review board or ethics committee of each participating clinical centre, and all participants
provided informed consent. All 10,251 ACCORD participants were randomised to either
intensive glucose control (HbA1c<6.0% [42 mmol/mol]) or standard glucose control (HbA1c
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between 7.0% [53 mmol/mol] and 7.9% [63 mmol/mol]). In addition, 5,518 participants
were assigned to the Lipid Study and randomised to receive a blinded lipid drug that was
either fenofibrate 160 mg or placebo, in addition to open-label simvastatin therapy. Statins
were titrated to achieve LDL-cholesterol targets for primary and secondary cardiovascular
protection, with a maximum dose of 40 mg simvastatin (or equivalent). Other concomitant
prescription lipid therapies were not permitted, as per the protocol. The study concluded in
June 2009, and resulted in no statistical difference in the primary outcome, a composite of
non-fatal myocardial infarction, non-fatal stroke and cardiovascular death. The results of the
Lipid Study have previously been reported [14].
Study participants
Participants were eligible to enrol in the ACCORD study if they had type 2 diabetes,
possessed a HbA1c between 7.5% [59 mmol/mol] and 11% [96.72 mmol/mol] and were
either (a) between the ages of 40 and 79 years with CVD, or (b) between the ages of 55 and
79 with either evidence of subclinical CVD or the presence of two or more additional risk
factors for CVD. In addition, to be eligible for the Lipid Study, participants had to meet the
following criteria: an estimated off-statin LDL-cholesterol level of 1.55–4.65 mmol/l; an
HDL-cholesterol level below 1.42 mmol/l for women and black participants, or below 4.5
mmol/l for all other groups; and a triacylglycerol level below 8.5mmol/l if untreated or
below 4.52 mmol/l if the participants were currently taking lipid-lowering medication.
Potential participants were excluded from the ACCORD study if their serum creatinine was
greater than 132.6 µmol/l owing to the anticipated use of metformin in the trial.
Lipid study procedures
Participants were randomised to either statin therapy alone or statin plus fenofibrate therapy
using a centralised randomisation procedure and permuted blocks. During the main
ACCORD Lipid Trial, all Lipid Study participants were started on open-label simvastatin
(during the Vanguard phase, participants were started on statin therapy only if their LDL-
cholesterol level was greater than 3.00 mmol/l); all Vanguard participants were placed on
statin when the main trial period began. One month after randomisation, participants were
started on either fenofibrate or a matching placebo tablet. The simvastatin dose was
consistent with national guidelines and was modified as the study progressed in response to
changing recommendations [15]. During the main study, all Lipid Study participants were
provided with either 20 or 40 mg/day of simvastatin based on risk profile and LDL-
cholesterol level.
The starting dose of fenofibrate was 160 mg/day. In 2004, procedures were changed to
adjust the ongoing dosing of fenofibrate to the estimated GFR (eGFR) using the
Modification of Diet in Renal Disease equation [16]. Participants with an eGFR ≥50 ml
min−1 1.73 m−2 received 160 mg/day of either fenofibrate or matching placebo, while those
with an eGFR between 30 and 50 ml min−1 1.73 m2 received 54 mg/day of fenofibrate or
placebo. If an eGFR fell below 30 ml min−1 1.73 m2 on two consecutive occasions, the
fenofibrate (but not the statin) was permanently discontinued.
In addition to lipid medications, glucose-lowering medications were also supplied to all
Lipid Study participants. A medication inventory of concomitant classes of medication was
obtained from participants at baseline and annually.
Designation as showing FACI
Lipid Study participants initiating full-dose fenofibrate at least 30 days prior to their 4-
month serum creatinine assessment were eligible for the study cohort examined in this
report. Those participants who also experienced at least a 20% rise in creatinine above their
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baseline creatinine value at the first on-medication creatinine measurement (month 4 of the
ACCORD study) were classified as having a fenofibrate-associated creatinine increase
(FACI).
Laboratory measurements
Serum creatinine was measured at baseline and every 4 months throughout the study. If an
eGFR fell below 30 ml min−1 1.73 m2, participants were asked to undergo a repeat serum
creatinine measurement within 2 weeks to confirm the value. Analysis of serum creatinine
was performed using the Roche Creatinine Plus enzymatic method (Roche Diagnostics,
Basel, Switzerland) on a Modular P analyser. The method is based on conversion of the
creatinine present in a sample to sarcosine using creatininase and creatinase enzymes. The
results obtained by this procedure are traceable to the isotope dilution mass spectrometry
reference method. The sensitivity of the Creatinine Plus assay is 2.29 µmol/l. The intra-assay
CVs based on an analysis of low- and high-quality control samples were 0.8 and 0.7%,
respectively, whereas the interassay CVs were 1.6 and 2.5%, respectively.
Urine was collected at baseline, at 2 years and 4 years, and at the end of the study from all
participants. Serum and urine creatinine were determined enzymatically on a Roche Double
Modular P Analytics automated analyser. Interassay precision is consistently <1.4% for the
high-quality and <2.2% for the low-quality control samples. Urine albumin was determined
by immunonephelometry on a Siemens BN II nephelometer (Siemens Healthcare
Diagnostics, Tarrytown, NY, USA). The sensitivity of the assay is 1.6 g/l with interassay
CVs of 3.0, 2.6 and 4.9% for control levels of 8.9 g/l, 66 g/l, and 161 g/l, respectively. All
serum and urine samples were analysed on the day of sample receipt. Microalbuminuria was
defined as an albumin/creatinine ratio of ≥3.5 mg/mmol but <35 mg/mmol in a random urine
sample, and macroalbuminuria was defined as an albumin/creatinine ratio≥35 mg/mmol.
Statistical analysis
Descriptive statistics (means and SDs of continuous factors, and frequencies and
percentages of categorical factors) were computed by FACI status, and groups were
compared using univariable logistic regression models. Analyses of factors related to FACI
were limited to participants assigned to fenofibrate treatment. Relationships were examined
between FACI and (1) baseline demographic and medical characteristics; (2) baseline and
early (4-month) on-treatment medication use; and (3) early changes in clinical measures.
Factors with a demonstrated or postulated relationship to renal function on fenofibrate were
considered. A ‘best’ multivariable logistic regression model to predict FACI status was
constructed using a best subsets variable selection procedure based on the score statistic
from fitted models. All variables presented in Tables 1, 2 and 3 below were considered as
candidates. The top five models of each size up to 20 covariates were considered. The model
with the smallest Akaike Information Criterion and all candidate variables significant at the
0.05 alpha-level were chosen. The relationship between FACI status and baseline to end-of-
study change in urinary albumin/creatinine ratio was assessed by analysis of covariance of
the within-subject differences in the log10 transformation of the ratios. Relationships
between FACI status and time to follow-up renal outcome (incident micro- and
macroalbuminuria) and to fatal/non-fatal CVD event were assessed using proportional
hazards regression models. Each model examined included factors selected in the final
logistic regression model for FACI to control for potential confounders. Distributions of the
temporal change in renal function were examined using box-and-whisker plots of the
follow-up minus baseline difference in serum creatinine and eGFR [17]. All analyses were
performed using SAS version 9.2 software (SAS Institute Inc., Cary, NC, USA).
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A total of 5,518 participants were enrolled in the ACCORD Lipid Study, with 2,765
randomised to receive fenofibrate plus statin and 2,753 to receive placebo plus statin. The
baseline creatinine (mean±SD) was 70.92±17.54 µmol/l in the fenofibrate arm and
70.92±17.54 µmol/l in the placebo arm. At the 4-month visit, the serum creatinine had
increased to 83.12±23.64 µmol/l in the fenofibrate arm and was unchanged (70.16±17.54
µmol/l) in the placebo arm. This difference was statistically significant (p<0.0001). Among
participants assigned to fenofibrate treatment, 2,523 (91%) were placed on full-dose
medication at least 30 days prior to the 4-month serum creatinine assessment. Of those,
1,212 participants (48%) met the criteria for FACI (>20% increase in serum creatinine at the
4-month follow-up visit) compared with 223 (9%) of placebo patients. Subsequent to the 4-
month creatinine measurement, 2,462 (98%) remained active in the Lipid Trial. Of the 1,191
active participants in the FACI group, 316 (26%) were placed on a reduced dose of
fenofibrate and 419 (35%) stopped active medication at some point after the 4-month visit.
Among 1,271 active participants in the group with <20% increase in serum creatinine (no
FACI), 235 (18%) were placed on a reduced dose of fenofibrate, and 327 (26%) stopped
active medication at some point after the 4-month visit.
Characteristics predicting creatinine elevation
In univariate analysis, several baseline demographic and medical characteristics were
associated with meeting the criteria for entry into the FACI group. These are described in
Table 1. Briefly, participants were more likely to experience FACI if they were male and
non-Hispanic white, had a longer duration of diabetes, had pre-existing kidney disease as
defined by the presence of micro- or macroalbuminuria at baseline, were randomised to the
intensive glycaemia group, or had a history of clinical CVD at baseline.
Univariable relationships between selected medication use at study entry and at month 4 and
FACI at month 4 are described in Table 2. A larger number of participants in the FACI
group were treated at baseline with an ACE inhibitor, a loop diuretic, a thiazide diuretic or a
statin. We also found that the treatment with a thiazolidinedione (TZD) medication for
management of diabetes in the first 4 months of the trial was associated with FACI
classification by the 4-month visit.
Univariable relationships between baseline and 4-month clinical characteristics and FACI
status at 4 months are shown in Table 3. Participants in the FACI group had a lower average
creatinine (higher eGFR) at baseline and a higher log10 urine albumin/creatinine ratio. LDL-
cholesterol level was lower in the participants with FACI compared with those without, and
triacylglycerol level was higher. No differences were seen in baseline HDL-cholesterol or
baseline BP values. Examination of the change in clinical characteristics from baseline to
month 4 showed that participants with FACI had a greater mean increase in HDL-
cholesterol and greater reductions in triacylglycerol levels. Participants in the FACI group
also showed greater reductions in systolic and diastolic BP.
In multivariable logistic regression analysis adjusted for factors selected via forward
variable selection to predict FACI group status (Table 4), participants with FACI were more
likely to be older and male, and have a longer duration of diabetes, a baseline history of
CVD, higher triacylglycerol levels, higher systolic BP, and lower baseline levels of serum
creatinine and LDL-cholesterol. They were also more likely to experience a greater
reduction in triacylglycerol levels and systolic BP during the first 4 months of treatment.
On-study use of TZD by month 4 of the ACCORD study also predicted allocation to FACI
status.zxz
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Long-term renal and cardiovascular outcomes
The fenofibrate-associated increase in creatinine and decrease in GFR as estimated by the
chronic kidney disease-epidemiology (CKD-EPI) equation [17] was stable over time, as
indicated by the box-and-whisker plot of change in Fig. 1. An examination of FACI status vs
long-term renal and CVD events, and change in urinary albumin/creatinine ratio is presented
in Table 5. We found no significant differences in relationships between FACI status and
incident microalbuminuria, macroalbuminuria or end-stage renal disease, mean change in
urine albumin/creatinine ratio, or occurrence of fatal or non-fatal CVD events (the primary
outcome of the ACCORD study).
Discussion
In this epidemiological analysis of the ACCORD Lipid Study participants, we found that
48% of the participants randomised to receive fenofibrate and 9% of those randomised to
receive placebo had at least a 20% increase in serum creatinine shortly after starting on
blinded study medication. Analysis of the participants in the fenofibrate arm who met this
criterion were more likely to be older and male, to have existing CVD, to be taking an ACE
inhibitor or a diuretic at the time of starting fenofibrate, to possess lower serum creatinine
and LDL-cholesterol levels at the time of randomisation, and to be randomised to intensive
glycaemic control compared with the participants in the fenofibrate arm who did not
experience a 20% increase in creatinine. Concurrent use of a TZD for blood glucose control
was also strongly associated with experiencing an increase in creatinine level. Participants
were regularly tested for renal function, and reductions in medications were implemented as
indicated. In this context, no significant adverse effects on other measures of renal function
were seen during the trial among those who met the FACI criteria. In addition, participants
meeting the FACI criteria had the same rate for the ACCORD primary cardiovascular
outcome as did those who did not.
Those participants treated with fenofibrate who experienced an increase in creatinine level
also showed a greater decrease in serum triacylglycerol level, a greater increase in HDL-
cholesterol, and greater reductions in both systolic and diastolic BP at month 4 of the study.
These greater responses in terms of triacylglycerols, HDL-cholesterol and BP are consistent
with the hypothesis that participants in the FACI group were more sensitive to fenofibrate
treatment. Additional studies will be necessary to determine whether these individuals can
be identified through genetic analyses, and pharmacogenomic studies may be warranted. In
this regard, it is interesting to note that the frequency of the peroxisome proliferator-
activated receptor (PPAR) alpha G/C intron 7 gene polymorphism has been associated with
a greater triacylglycerol-lowering response to fenofibrate in patients with type 2 diabetes
mellitus [18].
Many of the characteristics that we found to be associated with FACI were not surprising.
Medications with a known association with a change renal function were predictive, as were
characteristics associated with advanced disease, such as duration of diabetes. Interestingly,
we found a strong association of an increase in creatinine level among participants also
treated with a TZD. The basis for this finding is unclear. ATZD was used by 74% of
participants in the ACCORD study. Fenofibrate is a PPAR-alpha agonist, and rosiglitazone,
the TZD used most often in ACCORD, is a PPAR-gamma agonist. TZDs have been noted to
increase creatinine in some patients with diabetes [19], and the combination of a TZD and
fenofibrate may have had an additive effect. There does not appear to be any long-term
adverse effect on renal function from the combination, a finding that confirms a recent study
in diabetes-induced experimental nephropathy [20]. In univariable analysis, individuals
randomised to intensive glycaemia treatment were more likely to experience FACI;
however, intensive glycaemic treatment was not selected in the final multivariable logistic
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regression model. Given the association of TZD with FACI, this association is likely to
reflect the increased use of TZD in this group [21].
Our results confirm that fenofibrate use increases serum creatinine level surprisingly often.
This finding is consistent with those of previous studies [4, 11, 22, 23]. The underlying
mechanism of the increase is still, however, unclear. Changes in GFR, creatinine excretion
within the kidney tubules, altered renal haemodynamics and changes in production of
creatinine by skeletal muscle have all been hypothesised [9, 11, 24]. In a crossover study of
fenofibrate and placebo, Ansquer et al did not find a significant change in GFR as measured
by inulin clearance, tubular creatinine secretion as measured by urinary/plasma creatinine to
urinary/plasma inulin ratio, or total creatinine excretion as measured by 24 h urinary
creatinine collection [11]. Other investigations have not documented any changes in renal
blood flow as measured by para-aminohippurate [24]. Another possible mechanism is
increased production of creatinine from muscle. Hottelart et al [24] did note an increase in
the products of muscle breakdown in some patients taking fenofibrate, but this was not
correlated with an increase in serum creatinine. Thus, this potential mechanism does not
appear to account for the increase seen.
The mechanism(s) underlying increased plasma creatinine with fenofibrate and other PPAR-
alpha activators is likely to be complex given the wide tissue distribution and broad range of
genes regulated by this transcriptional activator, which may include genes related to creatine
synthesis, metabolism and transport [25, 26]. For example, it has been noted that fibrates
alter the production of renal eicosanoids, which may affect renal blood flow [4, 27]. It is
interesting to note that the concomitant administration of ACE inhibitors and diuretics,
agents that are associated with azotaemia due to altered renal blood flow, was increased
among patients experiencing FACI while taking fenofibrate. This suggests a common
mechanism(s). More work is needed to better understand the mechanisms that underlie this
change.
Preservation of long-term renal function among those randomised to fenofibrate has been
previously reported by the FIELD investigators [23]. Davis et al, in a study of renal function
among FIELD participants participating in a washout study, found that those participants
randomised to fenofibrate had an eGFR closer to baseline values than did participants
randomised to placebo [23]. We were able to confirm that, among individuals who showed
an increase in creatinine level immediately upon starting fenofibrate, no long-term adverse
renal effects or any increased risk of the main study outcome, CVD, was seen. The overall
trend was towards a slight protective effect with a smaller change in urinary albumin/
creatinine ratio and fewer participants developing microalbuminuria, although neither of
these findings was statistically significant. This relationship may have been somewhat
attenuated by the greater number of participants meeting FACI status who had a protocol-
mandated reduction in fenofibrate dose or cessation of fenofibrate therapy compared with
those who did not meet FACI status. The occurrence of micro- and macroalbuminuria was
significantly reduced by fenofibrate treatment in the full ACCORD Lipid Study cohort [14].
These findings suggest that fenofibrate might act via pathways similar to ACE inhibitors,
which raise creatinine while being ‘reno-protective’. In this regard, it is of interest that
treatment with ACE inhibitors at baseline predicted increases in creatinine levels during
fenofibrate therapy.
A number of factors limit the interpretation of these data. First, the generalisability of results
to individuals without diabetes or others not similar to the ACCORD participants is limited.
Second, the defined cut-point of a 20% rise in serum creatinine is based on clinical
considerations and is arbitrary; a different cut-point may have altered the results. Third, we
do not have data on other independent markers of renal function such as cystatin for the
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ACCORD participants and were unable to conduct more rigorous and direct measurements
of renal function (e.g. inulin clearance) that could have provided insights into the pathways
involved in our findings. Additionally, the risk model’s R2 value of 14.9%indicates that
there are other determinants governing the development of FACI that are still unknown.
Finally, it is possible that, in routine clinical practice, outcomes could be worse if renal
surveillance and timely adjustments in fenofibrate doses were carried out less consistently
than in the ACCORD research protocol.
These limitations must be balanced against the strengths of the study. This is one of largest
clinical trials of fenofibrate, and participants were followed for an extended period of time.
The size and duration provide for stable estimates of the creatinine increase. We were able
to examine the effects of fenofibrate among those participants who experienced the increase,
and found no adverse effect on end-stage renal disease or albuminuria. Finally, we identified
factors such as older age, male sex and existing CVD as risk factors for increased serum
creatinine level, and found that the risk of creatinine elevation was higher in those treated
with TZDs and certain classes of antihypertensive medication.
In conclusion, we have identified clinical characteristics that predict which patients with
diabetes treated with fenofibrate will develop an increase in creatinine level. We have also
confirmed that no long-term adverse effects are seen on renal function, and that those
individuals who experience the increase in creatinine may be more sensitive to the proposed
beneficial effects of fenofibrate; they may, for example, show greater clinical benefit as
indicated by reductions in serum triacylglycerols and increases in HDL-cholesterol.
Participants meeting the FACI criteria who had appropriate adjustments to their medication
did not have a greater incidence of renal or cardiovascular endpoints.
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Box-and-whisker plots of the distribution of follow-up minus baseline difference in serum
creatinine (a) and eGFR (b) for participants without FACI (empty boxes on left at each time
point) and with FACI (grey-filled boxes on right at each time point). Rectangles depict the
lower quartile (bottom), median (solid line inside box) and upper quartile (top) of the
difference. The black dot inside the rectangle shows the mean. Whiskers extend to 1.5 times
the interquartile range above and below the rectangles, with grey dots showing individual
values beyond 1.5 inter-quartile ranges below the 25th or above the 75th percentiles
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Table 1








Randomised to INT (%) 53 (638) 45 (593) 1.35 (1.15, 1.57) 0.0002
Age (years) 62 (7) 62 (7) 1.05 (0.97, 1.13) 0.3
Female (%) 28 (1,212) 32 (422) 0.80 (0.68, 0.95) 0.01
Race/ethnicity (%) 0.08
  Non-Hispanic white 69 (841) 64 (843)
  African-American 13 (152) 14 (186) 0.82 (0.65, 1.04)
  Hispanic 7 (80) 9 (111) 0.72 (0.53, 0.98)
  Asian 6 (75) 7 (85) 0.88 (0.64, 1.22)
  Other 5 (64) 7 (86) 0.75 (0.53, 1.05)
Microalbuminuriab (%) 33 (393) 28 (367) 1.24 (1.04, 1.47) 0.01
Macroalbuminuriab (%) 8 (99) 6 (75) 1.47 (1.07, 2.00) 0.02
Duration of diabetes (years)c 11 (8) 10 (7) 1.12 (1.03, 1.22) 0.006
History of clinical CVD (%) 38 (464) 34 (444) 1.21 (1.03, 1.43) 0.02
Values are % (n) or mean (SD)
INT, intensive arm of glycaemia study
a
OR for 1 SD increase for continuous factors
b
n= 1,205 for FACI and 1,304 for non-FACI
c
n= 1,202 for FACI and 1,298 for non-FACI
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Table 2
Association of medication use at baseline and month 4 of the study, and the change in use from baseline to









  Insulin 33 (402) 34 (441) 0.98 (0.83, 1.16) 0.8
  ACE inhibitor 57 (693) 50 (656) 1.33 (1.14, 1.56) 0.0003
  Angiotensin-receptor blocker 13 (163) 15 (202) 0.85 (0.68, 1.07) 0.2
  TZD 18 (223) 17 (228) 1.07 (0.87, 1.31) 0.5
  Aspirin 59 (712) 57 (748) 1.07 (0.91,1.26) 0.4
  Loop diuretic 11 (127) 8 (100) 1.42 (1.08, 1.87) 0.01
  Thiazide diuretic 29 (354) 25 (325) 1.25 (1.05, 1.49) 0.01
  Potassium-sparing diuretic 2 (29) 3 (36) 0.87 (0.53, 1.43) 0.6
  Statin 63 (765) 56 (736) 1.34 (1.14, 1.57) 0.0004
  Non-steroidal anti-inflammatory drug 3 (30) 2 (32) 1.01 (0.61, 1.68) 0.9
Medications at month 4 of study (%)
  >20 mg simvastatina 5 (55) 4 (43) 1.35 (0.90, 2.02) 0.2
  Insulinb 45 (533) 42 (545) 1.11 (0.94,1.30) 0.2
  TZDb 59 (707) 44 (570) 1.84 (1.57, 2.16) <0.0001
Values are % (n)
a
n= 1,154 for FACI and 1,199 for no-FACI
b
n= 1,192 for FACI and 1,290 for no-FACI
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Table 4
Multivariable logistic regression model to predict FACI >20% at month 4 of the study
Variable ORa (95% CI) p value
Age (SD change 7 years) 1.12 (1.02, 1.24) 0.02
Female 0.59 (0.46, 0.74) <0.0001
Duration of diabetes (SD change 7.5 years) 1.11 (1.01, 1.22) 0.03
Baseline history of CVD 1.30 (1.06, 1.59) 0.01
Baseline use of ACE inhibitor 1.33 (1.10, 1.60) 0.003
Baseline use of loop diuretic 1.42 (1.01, 2.00) 0.04
Baseline use of thiazide diuretic 1.38 (1.11, 1.72) 0.003
Baseline serum creatinine (SD change 15.25 µmol/l) 0.71 (0.64, 0.79) <0.0001
Baseline LDL-cholesterol (SD change 0.78 mmol/l) 0.86 (0.78, 0.95) 0.002
Baseline triacylglycerol level (SD change 1.14 mmol/l) 1.39 (1.23, 1.58) <0.0001
Month 4 minus baseline triacylglycerol (SD change 1.27 mmol/l) 0.71 (0.62, 0.81) <0.0001
Baseline systolic BP (SD change 18 mmHg) 1.51 (1.34, 1.70) <0.0001
Month 4 minus baseline systolic BP (SD change 17 mmHg) 0.67 (0.60, 0.75) <0.0001
Change in use of TZD from baseline to month 4 of the study <0.0001
 No baseline TZD, no month 4 TZD Reference
 No baseline TZD, on TZD month 4 2.19 (1.78, 2.69)
 On baseline TZD, no month 4 TZD 1.18 (0.46, 3.03)
 On baseline TZD, on TZD month 4 1.56 (1.20, 2.03)
Results of best subsets variable selection procedure using score statistics (n= 2,054; 984 FACI; 1,070 no FACI; max-rescaled R2= 14.9% [28])
a
OR for 1 SD increase for continuous factors
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